

Versatile Access to Martin's Spirosilanes and Their Hypervalent Derivatives


Hugo Lenormand,[‡] Vincent Corcé,[‡] Geoffroy Sorin,[‡] Christine Chhun,[‡] Lise-Marie Chamoreau,[‡] Lahouari Krim,[§] Emilie-Laure Zins,[§] Jean-Philippe Goddard,^{*,‡} and Louis Fensterbank^{*,‡}

[‡]Sorbonne Universités UPMC Université Paris 06, UMR CNRS 8232, Institut Parisien de Chimie Moléculaire, 4 place Jussieu, CC 229, F-75005 Paris, France

[§]Sorbonne Universités, UPMC Université Paris 06, UMR CNRS 8233, MONARIS, 4 place Jussieu, CC 49, F-75005 Paris, France


S Supporting Information

ABSTRACT: A new route to Martin's spirosilanes has been devised. The original synthesis does not allow diversely substituted spirosilane derivatives to be synthesized, and thus their corresponding silicates. In this report, Martin's spirosilanes bearing alkyl, aryl, halogen, alkoxy, and trifluoromethyl substituents on the aryl ring have been prepared through a versatile four-step route. Addition of fluoride onto these Lewis acids as a prototypical reaction with a nucleophile yielded a library of stable fluorosilicates. Both sets of compounds have been characterized by X-ray crystallography.



Silicon, among a number of other elements, has the ability to become hypervalent. Penta- or hexacoordinate derivatives can be obtained by reaction of electrophilic tetravalent compounds with nucleophiles. The so-called 3 centers–4 electrons hypervalent bond emerged from years of controversy¹ and was finally accepted as the description of this particular bonding pattern.² This important structural alteration impacts the reactivity and properties of the silicon derivatives and allows a broad spectrum of applications. As the first discovered hypervalent silicon compound, by Gay-Lussac³ in the beginning of the 19th century, hexafluorosilicate anion is still used in material sciences, health care, or photovoltaic devices.⁴ Hypervalent silicates are now encountered in numbers of organic and organometallic transformations.⁵ In 1979, Martin reported the preparation of bis(α,α -bis(trifluoromethyl) benzenemethanolato(-2) C^2,O) silane **1** as a versatile precursor of stable pentavalent silicon derivatives (Scheme 1).⁶

Scheme 1. Synthetic Routes to Martin's Spirosilanes



Nucleophilic attack on the silicon atom of **1** triggers strain release and synergic stabilization provided by the electro-negative bistrifluoro alkoxy ligands leads to a trigonal bipyramidal pentavalent adduct. Indeed, the trifluoromethyl groups withdraw electrons from the apical oxygen atoms that are themselves more able to accept extra electron density from the hypervalent O–Si–O bond.⁷ Due to this particular environment, **1** behaves as a strong Lewis acid. For instance, it has been used not only as a catalyst in the polymerization of cyclohexene oxide,⁸ but also in the reduction of carbonyl compounds through a hydridosilicate derivative.⁹ Recently, Martin's spirosilane **1** was engaged in the synthesis of hypervalent silicon species containing a Si–Si bond.¹⁰ We have also shown that **1** could be used as a probe for the detection of NO¹¹ and fluoride.¹²

Martin's synthesis is still the most efficient way to prepare **1**.⁶ Deprotonation of the commercially available hexafluorocumyl alcohol followed by ortholithiation using 2.2 equiv of *n*-BuLi in the presence of 10 mol % TMEDA afforded the corresponding dilithiated intermediate that reacts with silicon tetrachloride. After crystallization and sublimation, **1** is obtained in 42% yield.


This reliable preparation cannot be extended to analogues with substituted aryl moieties presumably because of the lack of regiocontrol in the ortholithiation step. In order to solve this, we developed a strategy based on orthobromo precursors **2**. Thus, deprotonation followed by bromide/lithium exchange would generate the corresponding dilithiated intermediates which should react with SiCl₄ to afford new Martin's spirosilane analogues **3** (Scheme 1).

Received: December 16, 2014

Published: February 19, 2015

The major issue in the preparation of precursors **2** resides in the introduction of the 2-hydroxy-1,1,1,3,3,3-hexafluoro-prop-1-yl group at the desired position. This reaction has been accomplished by using hexafluoroacetone (HFA) as an electrophile to trap Grignard reagents¹³ or in aromatic electrophilic substitution.¹⁴ However, due to its high toxicity and the difficulty handling this gaseous compound, we turned our attention to a reported method for the introduction of the two trifluoromethyl groups.¹⁵ Commercially available ortho-bromo benzoic acids **4a–i** have been esterified with pentafluorophenol in the presence of DCC (dicyclohexylcarbodiimide) to afford esters **5a–i** in good to excellent yields (75–98%) (Scheme 2). These activated esters reacted with Ruppert-

Scheme 2. Synthesis of Precursors **2a–i**



^aThe alcohol function was partially desilylated after workup.

Prakash reagent (TMSCF₃) in the presence of a catalytic amount of TBAF.¹⁶ Two successive nucleophilic additions of the trifluoromethyl anion occurred at the benzylic position to generate silyl ethers **6a–i** in high yields. When the aromatic ring was substituted by an electron withdrawing group (**5d**, **5e**, **5g**), the alcohol function was partially desilylated. Subsequent treatment with aqueous hydrochloric acid (6N) in THF was necessary to fully deprotect the alcohol group and obtain spirosilane precursors **2a–i** in good to excellent yields.

With this set of substrates in hand, we screened experimental conditions in order to optimize the preparation of the corresponding spirosilanes derivatives **3a–i**. First, we used an excess of *t*-BuLi to perform the deprotonation—bromide/lithium exchange sequence from **2a**.¹⁷ All attempts were unsuccessful and only debrominated hexafluorocumyl alcohol was obtained. Therefore, we concluded that this was due to uncontrolled protonation of the aryllithium intermediate. This observation was consistent with some very interesting work by Beak¹⁸ who showed with different substrates bearing an acidic proton and an exchangeable halide that the faster deprotonation is followed by rapid halogen–lithium exchange to give a dilithiated intermediate. This intermediate then reacts in an intermolecular fashion with starting material and gets protonated. Thus, the desired dilithiated intermediate cannot form in satisfactory fashion. To overcome this issue, alcohols **2a–i** were initially deprotonated by an equimolar amount of sodium hydride to form the intermediate sodium alkoxide at rt (Table 1). The reaction mixture was cooled to –78 °C followed by the addition of *t*-BuLi (2.2 equiv). The solution was warmed to 0 °C to afford the corresponding dilithiated intermediate, and then, silicon tetrachloride was added

Table 1. Preparation of Spirosilanes **1** and **3b–i**

Entry	Substrate	Product	Yield
		1. NaH (1.1 equiv.) Et ₂ O, 15 min, rt 2. <i>t</i> -BuLi (2.2 equiv.) Et ₂ O, 1.5 h, –78 °C to 0 °C 3. SiCl ₄ (0.6 equiv.) 15 h, 0 °C to rt	
1			1 , 72%
2			3b , 71%
3			3c , 70%
4		-	-
5			3e , 67%
6			3f , 65%
7			3g , 73%
8			3h , 54%
9			3i , 80%

dropwise at 0 °C to the reaction mixture. After workup, spirosilane derivatives **3** were obtained by crystallization.

Using this method, the reference Martin's spirosilane **1** was obtained in 72% overall yield as an analytically pure sample (Table 1, entry 1). Compound **2d** (Table 1, entry 4) did not allow the formation of the corresponding spirosilane, due to the incompatibility of the nitro group with *t*-BuLi, and led to the degradation of the starting material. The electronics of the aromatic ring did not exhibit particular influence on the formation of the spirosilane derivatives as **3b** (71%) and **3c** (70%) bearing an electron donating group (Me and OMe, respectively) and were isolated in comparable yields to **3g** (73%) substituted by a CF₃ electron withdrawing group (Table 1, entries 2 and 3 vs entry 7). However, steric hindrance seemed to play an important role. When **2h** was reacted to form spirosilane **3h**, the presence of the methyl group at the ortho position of the bromide affected the addition onto the silicon center and the yield decreased to 54% (Table 1, entry 8). Naphthyl precursor **2i** allowed access of **3i** in 80% yield, giving rise to a new class of spirosilanes (Table 1, entry 9). We confirmed the structures of **3b**, **3h**, and **3i** (Figure 1) by X-ray





Figure 1. Crystal structure of fluorosilicate **7c**-(Na).

diffraction analysis. In order to generate stable hypervalent species from spirosilanes **1** and **3b–i**, we decided to choose nucleophiles that form a strong bond to silicon.

Due to its high affinity for silicon, we selected fluoride for that purpose,¹⁹ and we investigated NaF and TBAF as sources of fluoride. Reactions of **1** and **3b–g** with NaF were run in acetone/water (1000/1) mixture at rt (Scheme 3). In less than 45 min, conversions were total and the corresponding fluorosilicates **7a–g** were obtained in excellent yields, higher than 94%. All products were isolated as stable solids. Their ²⁹Si NMR shifts were all around –80 ppm, consistent with a pentavalent silicon nucleus. Hypervalent compound **7c**-(Na) was crystallized in an acetone/cyclohexane mixture. The crystal structure was determined and showed a trigonal bipyramidal geometry of the silicon centers, which is in agreement with the reported structure of the fluorosilicate from **1** (Figure 1).²⁰ Both oxygen groups are at the apical position while the aromatic ring occupies the equatorial positions together with the fluorine atom. Of particular interest, the X-ray diffraction analysis shows a dimeric structure with two bridging sodium cations. Each of them are hexacoordinated with a water and

Scheme 3. Synthesis of Hypervalent Silicates **7a–i**, **8b**, **8c**, **8i**



acetone molecules (coming from the crystallization solvent), an oxygen atom of the hypervalent bond, and three fluorine atoms. Tetrabutylammonium fluorosilicates **7h** and **7i** were also accessible by treatment of the corresponding spirosilanes with TBAF in dichloromethane and were obtained in 92% and 97% yields, respectively. It is important to note that when **7h** had a sodium cation as counterion, the hypervalent compound was not stable enough to be isolated.

In conclusion, we have reported an efficient method to access diversely substituted Martin's spirosilane analogues. This four-step sequence relies on commercially available ortho-bromo benzoic acid derivatives and proceeds in high yields. The so-formed tetravalent spirosilanes serve as precursors for the preparation of fluorosilicates, obtained in excellent yields and high purity. Numerous applications such as anion sensing¹² and organocatalysis are currently under investigation in our laboratory.

EXPERIMENTAL SECTION

General Remarks. Reagents and chemicals were purchased from commercial sources and used as received. Unless otherwise noted, reactions were carried out under an argon atmosphere with magnetic stirring in redistilled solvents when necessary. Solvents were purified and dried by standard procedures: THF and Et₂O were distilled over sodium/benzophenone. *t*-Butyllithium was purchased from commercial sources as a 1.7 M solution in pentane and titrated before use.

SiCl₄ was distilled before use. Infrared (IR) spectra were recorded on an ATR spectrophotometer and only the strongest or the structurally most important peaks were listed. Melting points were determined in open capillary tubes and are uncorrected. ¹H, ¹⁹F, and ¹³C NMR spectra were recorded at room temperature at 400, 377, and 100 MHz, respectively, or at 300, 282, and 75 MHz, respectively. ²⁹Si NMR spectra were recorded at 119 MHz. Chemical shifts (δ) are reported in ppm and coupling constants (*J*) are given in Hertz (Hz). Abbreviations used for peak multiplicity are s (singlet); d (doublet); t (triplet); q (quartet); quat (quaternary); quint (quintet); sept (septet); m (multiplet); br (broad). Thin layer chromatographies (TLC) were performed on Merck silica gel 60 F 254 and revealed with a ultraviolet lamp (λ = 254 nm) and KMnO₄ staining. Flash Column Chromatographies were conducted on silica Geduran Si 60 Å (40–63 μm). High resolution mass spectrometries were performed on a LTQ Orbitrap (ESI) and on a microTOF (ESI).

Procedure A: Preparation of Pentafluorophenyl Ester. To a stirred solution of carboxylic acid (1.00 equiv) and pentafluorophenol (1.12 equiv) in THF (0.27 M) was added *N,N'*-dicyclohexylcarbodiimide (1.13 equiv) at room temperature. The progress of the reaction was monitored by TLC (petroleum ether/Et₂O mixture). The *N,N'*-dicyclohexylurea was removed by filtration and the filtrate was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel to afford the desired product.

Perfluorophenyl 2-Bromobenzoate (5a). Following the general procedure A with 2-bromobenzoic acid (14.81 g, 73.66 mmol), pentafluorophenol (15.18 g, 82.5 mmol) and *N,N'*-dicyclohexylcarbodiimide (17.17 g, 83.23 mmol) in 275 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 2% EtOAc) to afford **5a** (22.17 g, 60.4 mmol, 82%) as a white solid (mp 54 °C). ¹H NMR (300 MHz, CDCl₃): δ 8.14–8.06 (m, 1H), 7.82–7.74 (m, 1H), 7.53–7.43 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 161.6, 143.1, 141.5, 140.3, 139.9, 138.4, 136.4, 135.3, 134.5, 132.7, 128.6, 127.7, 123.4. ¹⁹F NMR (282 MHz, CDCl₃): δ –151.9 – –152.1 (m, 2F), –157.5 (t, *J* = 21.7 Hz, 1F), –162.0 – –162.2 (m, 2F). IR: ν = 2950, 1781, 1556, 1345, 1274, 1256, 1145, 1021, 999, 975, 822 cm⁻¹. HRMS (ESI+) calc. for C₁₃H₄BrF₅LiO₂ [M+Li]⁺ 372.9470; found 372.9467.

Perfluorophenyl 2-Bromo-5-Methylbenzoate (5b). Following the general procedure A with 2-bromo-5-methylbenzoic acid (16.93 g, 78.72 mmol), pentafluorophenol (16.23 g, 88.16 mmol) and *N,N'*-dicyclohexylcarbodiimide (18.35 g, 88.95 mmol) in 290 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 2% EtOAc) to afford **5b** (28.5 g, 74.79 mmol, 95%) as a white solid (mp 69 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.90 (d, *J* = 2.0 Hz, 1H), 7.64 (d, *J* = 8.2 Hz, 1H), 7.27 (d, *J* = 8.2, 2.0 Hz, 1H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 161.70, 142.7, 141.1, 140.2, 139.4, 138.5, 136.9, 137.9, 135.4, 135.0, 133.2, 128.2, 120.0, 20.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –151.9 – –152.3 (m, 2F), –157.7 (t, *J* = 21.6 Hz, 1F), –162.0 – –162.5 (m, 2F). IR: ν = 2929, 1773, 1520, 1286, 1243, 1186, 1068, 1007, 981, 822 cm⁻¹. HRMS (ESI+) calc. for C₁₄H₆BrF₅NaO₂ [M + Na]⁺ 402.9364; found 402.9344.

Perfluorophenyl 2-Bromo-5-methoxybenzoate (5c). Following the general procedure A with 2-bromo-5-methoxybenzoic acid (1.99 g, 8.6 mmol), pentafluorophenol (1.77 g, 9.63 mmol), and *N,N'*-dicyclohexylcarbodiimide (2 g, 9.72 mmol) in 32 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 5% Et₂O) to afford **5c** (3.14 g, 7.91 mmol, 92%) as a white solid (mp 64 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, *J* = 8.8 Hz, 1H), 7.59 (d, *J* = 3.1 Hz, 1H), 7.04 (dd, *J* = 8.8, 3.1 Hz, 1H), 3.87 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 161.5, 158.9, 142.6, 141.1, 140.1, 139.3, 138.6, 136.8, 136.0, 129.1, 120.9, 117.7, 113.6, 56.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –151.8 – –152.0 (m, 2F), –157.5 (t, *J* = 21.5 Hz, 1F), –162.0 – –162.2 (m, 2F). IR: ν = 2948, 1774, 1519, 1474, 1283, 1245, 1206, 1078, 1006, 894, 824 cm⁻¹. HRMS (ESI+) calc. for C₁₄H₆BrF₅NaO₃ [M + Na]⁺ 420.9292; found 420.9285.

Perfluorophenyl 2-Bromo-5-nitrobenzoate (5d). Following the general procedure A with 2-bromo-5-nitrobenzoic acid (1.23 g, 5

mmol), pentafluorophenol (1.03 g, 5.6 mmol), and *N,N'*-dicyclohexylcarbodiimide (1.17 g, 5.65 mmol) in 18 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 5% Et₂O) to afford **5d** (1.8 g, 4.37 mmol, 87%) as a pale yellow solid (mp 57 °C). ¹H NMR (300 MHz, CDCl₃): δ 8.93 (d, *J* = 2.7 Hz, 1H), 8.32 (dd, *J* = 8.8, 2.7 Hz, 1H), 8.01 (d, *J* = 8.8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 159.9, 147.1, 144.6, 143.1, 141.9, 139.6, 138.5, 124.5, 136.7, 130.7, 129.9, 128.3, 127.5. ¹⁹F NMR (282 MHz, CDCl₃): δ –151.6 – –151.9 (m, 2F), –156.3 (t, *J* = 21.7 Hz, 1F), –161.2 – –161.5 (m, 2F). IR: ν = 2981, 1760, 1496, 1254, 1236, 1176, 1054, 973, 851 cm⁻¹. HRMS (ESI-) calc. for C₇H₃BrNO₄ [M – C₆F₅]⁻ 243.9251; found 243.9252.

Perfluorophenyl 2-Bromo-5-fluorobenzoate (5e). Following the general procedure A with 2-bromo-5-fluorobenzoic acid (2.37 g, 10.81 mmol), pentafluorophenol (2.23 g, 12.1 mmol), and *N,N'*-dicyclohexylcarbodiimide (2.52 g, 12.21 mmol) in 40 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 2% Et₂O) to afford **5e** (3.83 g, 9.95 mmol, 92%) as a white solid (mp 97 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.82 (dd, *J*_{H-H} = 3.0 Hz, *J*_{H-F} = 8.5 Hz, 1H), 7.76 (dd, *J*_{H-H} = 8.8 Hz, *J*_{H-F} = 5.0 Hz, 1H), 7.23 (ddd, *J*_{H-H} = 8.8, 3.0 Hz, *J*_{H-F} = 7.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 161.4 (d, *J* = 250 Hz), 160.5, 142.7, 141.5, 140.2, 139.4, 138.7, 137.4, 136.8 (d, *J* = 7.5 Hz), 129.9 (d, *J* = 7.4 Hz), 122.0 (d, *J* = 22.1 Hz), 119.8 (d, *J* = 25.1 Hz), 117.9 (d, *J* = 3.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –112.7 (q, *J* = 7.8 Hz, 1F, F8), –151.9 – –152.0 (m, 2F), –157.0 (t, *J* = 21.7 Hz, 1F), –161.7 – –161.9 (m, 2F). IR: ν = 1762, 1593, 1516, 1484, 1322, 1296, 1237, 1216, 1156, 1070, 1036, 1010, 992, 879, 867, 840 cm⁻¹. HRMS (ESI+) calc. for C₁₃H₃BrF₆NaO₂ [M + Na]⁺ 406.9113; found 406.9129.

Perfluorophenyl 2-Bromo-4-fluorobenzoate (5f). Following the general procedure A with 2-bromo-4-fluorobenzoic acid (2.04 g, 9.33 mmol), pentafluorophenol (1.92 g, 10.45 mmol), and *N,N'*-dicyclohexylcarbodiimide (2.17 g, 10.54 mmol) in 35 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 3% Et₂O) to afford **5f** (3.37 g, 8.77 mmol, 94%) as a white solid (mp 76 °C). ¹H NMR (400 MHz, CDCl₃): δ 8.19 (dd, *J*_{H-H} = 8.8 Hz, *J*_{H-F} = 5.9 Hz, 1H), 7.53 (dd, *J*_{H-H} = 2.5 Hz, *J*_{H-F} = 8.2 Hz, 1H), 7.20 (ddd, *J*_{H-H} = 8.8, 2.5 Hz, *J*_{H-F} = 7.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 165.1 (d, *J* = 260 Hz), 160.6, 142.7, 141.2, 140.1, 139.4, 138.6, 136.8, 134.9 (d, *J* = 9.8 Hz), 125.3 (d, *J* = 10.2 Hz), 124.6 (d, *J* = 3.6 Hz), 123.0 (d, *J* = 24.8 Hz), 115.2 (d, *J* = 21.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –101.9 – –102.1 (m, 1F), –152.0 – –152.2 (m, 2F), –157.3 (t, *J* = 21.6 Hz, 1F), –161.9 – –162.1 (m, 2F). IR: ν = 1762, 1593, 1516, 1484, 1389, 1362, 1322, 1296, 1237, 1216, 1156, 1070, 1036, 1010, 992, 879, 867, 840 cm⁻¹. HRMS (ESI+) calc. for C₁₃H₃BrF₆NaO₂ [M + Na]⁺ 406.9113; found 406.9128.

Perfluorophenyl 2-Bromo-4-(trifluoromethyl)benzoate (5g). Following the general procedure A with 2-bromo-4-(trifluoromethyl)benzoic acid (1.28 g, 4.74 mmol), pentafluorophenol (977.4 mg, 5.31 mmol), and *N,N'*-dicyclohexylcarbodiimide (1.1 g, 5.35 mmol) in 18 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 1% Et₂O) to afford **5g** (2 g, 4.6 mmol, 97%) as a white solid (mp 60 °C). ¹H NMR (400 MHz, CDCl₃): δ 8.18 (d, *J* = 8.1 Hz, 1H), 8.04 (d, *J* = 2.2 Hz, 1H), 7.77–7.72 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 160.9, 142.7, 141.4, 140.1, 139.5, 138.8, 137.0, 136.0 (q, *J* = 33 Hz), 132.9, 132.3, 132.1 (q, *J* = 3.7 Hz), 124.6 (q, *J* = 3.6 Hz), 123.6, 122.5 (q, *J* = 273 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –63.5 (s, 3F, F8), –151.8 – –152.0 (m, 2F), –156.8 (t, *J* = 21.6 Hz, 1F), –161.6 – –161.8 (m, 2F). IR: ν = 1780, 1521, 1389, 1322, 1293, 1237, 1181, 1142, 1078, 1030, 999, 978 cm⁻¹. HRMS (ESI-) calc. for C₈H₃BrF₃O₂ [M – C₆F₅]⁻ 266.9274; found 266.9272.

Perfluorophenyl 2-Bromo-3-methylbenzoate (5h). Following the general procedure A with 2-bromo-3-methylbenzoic acid (922.6 mg, 4.29 mmol), pentafluorophenol (883.5 g, 4.8 mmol), and *N,N'*-dicyclohexylcarbodiimide (1 g, 4.85 mmol) in 16 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 5% Et₂O) to afford **5h** (1.47 g, 3.86 mmol, 90%) as a white solid (mp 63 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.80 (d, *J*

= 7.7 Hz, 1H), 7.48 (d, $J = 7.7$ Hz, 1H), 7.30 (t, $J = 7.6$ Hz, 1H), 2.50 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 162.4, 143.2, 141.4, 139.8, 138.1, 136.4, 125.2, 140.8, 135.1, 130.0, 129.4, 127.2, 124.6, 23.9. ^{19}F NMR (282 MHz, CDCl_3): δ -152.0 – -152.3 (m, 2F), -157.7 – -158.1 (m, 1F), -162.2 – -162.6 (m, 2F). IR: $\nu = 2975, 1771, 1518, 1280, 1263, 1244, 1175, 1143, 1115, 1086, 997, 905, 884\text{ cm}^{-1}$. HRMS (ESI+) calc. for $\text{C}_{14}\text{H}_6\text{BrF}_5\text{NaO}_2$ [$\text{M} + \text{Na}$] $^+$ 402.9369; found 402.9364.

Perfluorophenyl 1-Bromo-2-naphthoate (5i). Following the general procedure A with 1-bromo-2-naphthoic acid (1 g, 4 mmol), pentafluorophenol (824.6 mg, 4.48 mmol), and N,N' -dicyclohexylcarbodiimide (932.6 g, 4.52 mmol) in 15 mL of THF. The crude product was purified by flash column chromatography (petroleum ether 2% Et_2O) to afford **5h** (1.63 g, 3.92 mmol, 98%) as a white solid (mp 73 °C). ^1H NMR (400 MHz, CDCl_3): δ 8.56–8.50 (m, 1H), 7.98–7.87 (m, 3H), 7.76–7.62 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 162.8, 142.7, 141.1, 140.1, 139.4, 138.6, 136.9, 136.0, 132.7, 129.3, 129.2, 128.8, 128.5, 128.3, 127.5, 126.2, 125.4. ^{19}F NMR (376 MHz, CDCl_3): δ -151.7 – -152.0 (m, 2F), -157.4 – -157.6 (t, $J = 21.6$ Hz, 1F), -161.9 – -162.2 (m, 2F). IR: $\nu = 2925, 1771, 1516, 1460, 1374, 1323, 1308, 1263, 1223, 1208, 1169, 1151, 1073, 1029, 994, 957, 866, 820\text{ cm}^{-1}$. HRMS (ESI+) calc. for $\text{C}_{17}\text{H}_6\text{BrF}_5\text{NaO}_2$ [$\text{M} + \text{Na}$] $^+$ 438.9364; found 438.9355.

Procedure B: Preparation of Trimethyl [2,2,2-trifluoro-1-oxanyl-1-(trifluoromethyl)ethoxy] Silane. To a stirred solution of pentafluorophenyl ester **5** (1.00 equiv) in toluene (0.2 M) was added trimethyl(trifluoromethyl)silane (6.00 equiv). The reaction mixture was cooled to 0 °C in an ice bath and a solution of tetrabutylammonium fluoride (1 M in THF) (0.35 equiv) was added dropwise. The reaction mixture was allowed to reach room temperature and stirred for 18 h. The reaction was monitored by TLC (petroleum ether), and if necessary, additional trimethyl(trifluoromethyl)silane could be added. Diethyl ether was added and the organic phase was washed with aqueous HCl (1 M). The aqueous phase was extracted with Et_2O (2 times). The combined ethereal phases were washed with H_2O , dried over MgSO_4 , and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel to afford the desired product.

(2-(2-Bromophenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6a). Following the general procedure B with **5a** (18.52 g, 50.46 mmol), trimethyl(trifluoromethyl)silane (44.75 mL, 302.76 mmol) and tetrabutylammonium fluoride (17.66 mL, 17.66 mmol) in 190 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether 1% AcOEt) to afford **6a** (16.75 g, 42.39 mmol, 84%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 7.74 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.67 (d, $J = 8.2$ Hz, 1H), 7.39–7.30 (m, 1H), 7.26–7.21 (m, 1H), 0.25 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.5, 131.1, 130.0, 130.1 (quint, $J = 3.2$ Hz), 127.2, 123.0 (q, $J = 293$ Hz), 122.5, 82.0 (quint, $J = 30.0$ Hz), 1.7. ^{19}F NMR (376 MHz, CDCl_3): δ -70.4 (s, 6F, F9). IR: $\nu = 2944, 1756, 1575, 1544, 1489, 1378, 1345, 1286, 1256, 1178, 1054, 1005, 989, 851\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_9\text{H}_4\text{BrF}_6\text{O}$ [$\text{M} - \text{TMS}$] $^-$ 320.9355; found 320.9368.

(2-(2-Bromo-5-methylphenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6b). Following the general procedure B with **5b** (850 mg, 2.23 mmol), trimethyl(trifluoromethyl)silane (1.98 mL, 13.38 mmol) and tetrabutylammonium fluoride (0.78 mL, 0.78 mmol) in 9 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether) to afford **6b** (7.50 g, 18.3 mmol, 82%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 7.59 (d, $J = 8.1$ Hz, 1H), 7.44 (s, 1H), 7.05 (dd, $J = 8.1, 1.7$ Hz, 1H), 2.33 (s, 3H), 0.23 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.2, 137.1, 131.9, 130.8 (quint, $J = 2.9$ Hz), 130.1, 122.0 (q, $J = 293$ Hz), 119.1, 82.0 (quint, $J = 32.3$ Hz), 21.3, 1.8. ^{19}F NMR (376 MHz, CDCl_3): δ -70.4 (s, 6F). IR: $\nu = 2945, 1278, 1254, 1230, 1145, 1112, 1032, 981, 863, 867\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_{10}\text{H}_6\text{BrF}_6\text{O}$ [$\text{M} - \text{TMS}$] $^-$ 334.9512; found 334.9501.

(2-(2-Bromo-5-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6c). Following the general procedure B with **5c** (3.12 g, 7.87 mmol), trimethyl(trifluoromethyl)silane (6.98 mL, 47.22

mmol), and tetrabutylammonium fluoride (2.75 mL, 2.75 mmol) in 30 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether 2% Et_2O) to afford **6c** (2.41 g, 5.67 mmol, 72%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 7.62 (d, $J = 8.8$ Hz, 1H), 7.23 (d, $J = 2.8$ Hz, 1H), 6.81 (dd, $J = 8.8, 2.8$ Hz, 1H), 3.80 (s, 3H), 0.24 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 158.3, 137.9, 131.1, 123.3 (q, $J = 290$ Hz), 117.1 (quint, $J = 3.3$ Hz), 116.1, 112.6, 81.8 (quint, $J = 29.9$ Hz), 55.6, 1.6. ^{19}F NMR (376 MHz, CDCl_3): δ -70.4 (s, 6F). IR: $\nu = 2962, 1601, 1470, 1403, 1192, 1057, 1027, 963, 846, 761\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_{10}\text{H}_6\text{BrF}_6\text{O}$ [$\text{M} - \text{TMS}$] $^-$ 350.9461; found 350.9450.

(2-(2-Bromo-5-nitrophenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6d). Following the general procedure B with **5d** (1.75 g, 4.24 mmol), trimethyl(trifluoromethyl)silane (3.76 mL, 25.44 mmol), and tetrabutylammonium fluoride (1.48 mL, 1.48 mmol) in 16 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether 1% Et_2O) to afford **6d** (1.4 g, 3.18 mmol, 75%) as an orange liquid. ^1H NMR (300 MHz, CDCl_3): δ 8.62 (d, $J = 2.6$ Hz, 1H), 8.11 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.96 (d, $J = 8.8$ Hz, 1H), 0.27 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 138.8, 131.0, 125.3, 125.1, 124.8, 123.2, 119.5 (q, $J = 291$ Hz), 81.9. ^{19}F NMR (282 MHz, CDCl_3): δ -70.4 (s, 6F). IR: $\nu = 2973, 1580, 1481, 1432, 1376, 1176, 1089, 1060, 956, 882\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_9\text{H}_3\text{BrF}_6\text{O}_3$ [$\text{M} - \text{TMS}$] $^-$ 365.9206; found 365.9212.

(2-(2-Bromo-5-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6e). Following the general procedure B with **5e** (2.55 g, 6.64 mmol), trimethyl(trifluoromethyl)silane (5.89 mL, 39.84 mmol), and tetrabutylammonium fluoride (2.32 mL, 2.32 mmol) in 25 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether then petroleum ether 15% Et_2O) to afford **6e** (1.92 g, 4.65 mmol, 70%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 7.70 (dd, $J_{\text{H-H}} = 8.9$ Hz, $J_{\text{H-F}} = 5.8$ Hz, 1H), 7.42 (dd, $J_{\text{H-H}} = 2.9$ Hz, $J_{\text{H-F}} = 10.8$ Hz, 1H), 7.01 (ddd, $J_{\text{H-H}} = 8.9, 2.9$ Hz, $J_{\text{H-F}} = 6.8$ Hz, 1H), 0.25 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.1 (d, $J = 248$ Hz), 138.6 (d, $J = 7.6$ Hz), 132.2, 122.7 (q, $J = 293$ Hz), 118.4 (d, $J = 21.6$ Hz), 117.9 (dq, $J_{\text{C-F8}} = 26.9$ Hz, $J_{\text{C-F9}} = 3.0$ Hz), 116.7 (d, $J = 3.6$ Hz), 81.7 (t, $J = 29.4$ Hz), 1.7. ^{19}F NMR (376 MHz, CDCl_3): δ -70.5 (s, 6F), -113.2 (dt, $J = 11.4, 6.2$ Hz, 1F). IR: $\nu = 1585, 1474, 1395, 1226, 996, 960, 851, 761\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_9\text{H}_3\text{BrF}_7\text{O}$ [$\text{M} - \text{TMS}$] $^-$ 338.9261; found 338.9252.

(2-(2-Bromo-4-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6f). Following the general procedure B with **5f** (1.48 g, 3.84 mmol), trimethyl(trifluoromethyl)silane (3.40 mL, 23.04 mmol), and tetrabutylammonium fluoride (1.34 mL, 1.34 mmol) in 14 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether then petroleum ether 15% Et_2O) to afford **6f** (1.31 g, 3.15 mmol, 82%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 7.46 (dd, $J_{\text{H-H}} = 9.2$ Hz, $J_{\text{H-F}} = 5.7$ Hz, 1H), 7.30 (dd, $J_{\text{H-H}} = 2.8$ Hz, $J_{\text{H-F}} = 8.3$ Hz, 1H), 6.89 (ddd, $J_{\text{H-H}} = 9.3, 2.8$ Hz, $J_{\text{H-F}} = 7.1$ Hz, 1H), 0.24 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 162.4 (d, $J = 255$ Hz), 131.5, 126.5, 124.5 (d, $J = 24.0$ Hz), 123.3 (d, $J = 9.0$ Hz), 122.8 (q, $J = 291$ Hz), 114.4 (d, $J = 20.8$ Hz), 81.7 (quint, $J = 30.2$ Hz), 1.7. ^{19}F NMR (376 MHz, CDCl_3): δ -70.6 (s, 6F), -110.0 (m, 1F). IR: $\nu = 2963, 1603, 1549, 1494, 1290, 1248, 1223, 1196, 1153, 1138, 1042, 965, 948, 913, 868, 849\text{ cm}^{-1}$. HRMS (ESI-) calc. for $\text{C}_9\text{H}_3\text{BrF}_7\text{O}$ [$\text{M} - \text{TMS}$] $^-$ 338.9261; found 338.9250.

(2-(2-Bromo-4-(trifluoromethyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (6g). Following the general procedure B with **5g** (1.3 g, 3.00 mmol), trimethyl(trifluoromethyl)silane (2.66 mL, 18.00 mmol) and tetrabutylammonium fluoride (1.05 mL, 1.05 mmol) in 12 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether then petroleum ether 15% Et_2O) to afford **6g** (1.00 g, 2.16 mmol, 72%) as an orange liquid. ^1H NMR (400 MHz, CDCl_3): δ 8.00 (d, $J = 2.4$ Hz, 1H), 7.80 (d, $J = 8.6$ Hz, 1H), 7.61 (dd, $J = 8.6, 2.4$ Hz, 1H), 0.26 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 134.3 (q, $J = 3.9$ Hz), 133.1 (q, $J = 34$ Hz), 130.7 (quint, $J = 3.1$ Hz), 127.0, 124.0 (q, $J = 3.4$ Hz), 123.0, 122.7 (q, $J = 273$ Hz), 122.6 (q, $J = 290$ Hz), 81.9 (t, $J = 29.9$ Hz), 1.7. ^{19}F NMR (376 MHz, CDCl_3): δ -63.4 (s, 3F, F8), -70.4 (s, 6F, F9). IR: $\nu = 1390, 1334, 1286, 1247, 1219, 1199, 1140, 1089, 1051, 957, 943, 896,$

870, 849, 816 cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_{10}\text{H}_3\text{BrF}_9\text{O}$ [$\text{M} - \text{TMS}$]⁻ 388.9229; found 388.9238.

(2-(2-Bromo-3-methylphenyl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (**6h**). Following the general procedure B with **5h** (1.40 g, 3.68 mmol), trimethyl(trifluoromethyl)silane (3.26 mL, 22.08 mmol), and tetrabutylammonium fluoride (1.29 mL, 1.29 mmol) in 14 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether 2% Et_2O) to afford **6h** (1.30 g, 3.17 mmol, 86%) as an orange liquid. ¹H NMR (300 MHz, CDCl_3): δ 7.51 (d, $J = 8.1$ Hz, 1H), 7.37–7.31 (m, 1H), 7.27–7.20 (m, 1H), 2.49 (s, 3H), 0.20 (s, 9H). ¹³C NMR (75 MHz, CDCl_3): δ 141.9, 132.4, 130.7, 127.8, 126.6, 125.3, 123.1 (q, $J = 293$ Hz), 82.6 (quint, $J = 29.8$ Hz), 26.0, 1.7. ¹⁹F NMR (282 MHz, CDCl_3): δ -69.8 (s, 6F, F9). IR: $\nu = 1287, 1254, 1224, 1193, 1159, 1120, 1024, 979, 959, 871, 848$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_{10}\text{H}_6\text{BrF}_6\text{O}$ [$\text{M} - \text{TMS}$]⁻ 334.9512; found 334.9522.

(2-(1-Bromonaphthalen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-yloxy)trimethylsilane (**6i**). Following the general procedure B with **5i** (2.45 g, 5.96 mmol), trimethyl(trifluoromethyl)silane (5.28 mL, 35.76 mmol), and tetrabutylammonium fluoride (2.09 mL, 2.09 mmol) in 23 mL of toluene. The crude product was purified by flash column chromatography (petroleum ether 1% Et_2O) to afford **6i** (2.02 g, 4.53 mmol, 76%) as a colorless liquid. ¹H NMR (400 MHz, CDCl_3): δ 8.72–8.65 (m, 1H), 7.86–7.80 (m, 2H), 7.76–7.70 (m, 1H), 7.69–7.57 (m, 2H), 0.26 (s, 9H). ¹³C NMR (100 MHz, CDCl_3): δ 134.4, 134.0, 129.1, 128.3, 128.2, 128.0, 128.0, 127.7, 125.5, 125.00, 123.2 (q, $J = 289$ Hz), 82.9 (quint, $J = 29.7$ Hz), 1.8. ¹⁹F NMR (376 MHz, CDCl_3): δ -69.6 (s, 6F). IR: $\nu = 2966, 1197, 1154, 1007, 957, 855, 748$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_{13}\text{H}_6\text{BrF}_6\text{O}$ [$\text{M} - \text{TMS}$]⁻ 370.9512; found 370.9509.

Procedure C: Preparation of 1,1,1,3,3,3-Hexafluoro-2-arylpropan-2-ol. To a stirred solution of trimethyl[2,2,2-trifluoro-1-organyl-1-(trifluoromethyl)ethoxy]silane (1.00 equiv) in THF (0.2 M) was added 6 M HCl (half volume of THF). The reaction mixture was stirred overnight at room temperature. The mixture was diluted with H_2O and the product was extracted with Et_2O (2 times). The ethereal phases were combined, dried over MgSO_4 , and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel to afford the desired product.

2-(2-Bromophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2a**). Following the general procedure C with **6a** (9.97 g, 25.24 mmol), in 125 mL of THF and 60 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 1% EtOAc , then 6% EtOAc) to afford **2a** (7.83 g, 24.23 mmol, 96%) as a white solid (mp 43 °C). ¹H NMR (400 MHz, CDCl_3): δ 7.77–7.68 (m, 2H), 7.47–7.39 (m, 1H), 7.33 (td, $J = 7.7, 1.6$ Hz, 1H), 5.35 (s, 1H). ¹³C NMR (100 MHz, CDCl_3): δ 136.8, 131.7, 130.7 (quint, $J = 3.2$ Hz), 128.0, 127.6, 122.7 (q, $J = 289$ Hz), 120.4, 80.3 (t, $J = 29.3$ Hz). ¹⁹F NMR (376 MHz, CDCl_3): δ -73.6 (s, 6F). The spectroscopic data were consistent with those reported in the literature.^{6b}

2-(2-Bromo-5-methylphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2b**). Following the general procedure C with **6b** (974 mg, 2.38 mmol), in 12 mL of THF and 6 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et_2O) to afford **2b** (730 mg, 2.17 mmol, 91%) as a white solid (mp 52 °C). ¹H NMR (400 MHz, CDCl_3): δ 7.56 (d, $J = 8.2$ Hz, 1H), 7.50 (s, 1H), 7.13 (dd, $J = 8.2, 2.0$ Hz, 1H), 5.41 (s, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl_3): δ 138.2, 136.4, 132.6, 131.2 (quint, $J = 1.8$ Hz), 124.1 (q, $J = 282$ Hz), 127.1, 116.9, 82.5 (quint, $J = 32.3$ Hz), 21.3. ¹⁹F NMR (376 MHz, CDCl_3): δ -73.6 (s, 6F, F9). IR: $\nu = 3578, 2880, 1727, 1670, 1429, 1338, 1220, 1082, 997, 912, 761, 706$ cm^{-1} . HRMS calc. for $\text{C}_{10}\text{H}_6\text{BrF}_6\text{O}$ [$\text{M} - \text{H}$]⁻ 334.9512; found 334.9501. The spectroscopic data were consistent with those reported in the literature.^{17b}

2-(2-Bromo-5-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2c**). Following the general procedure C with **6c** (2.46 g, 5.79 mmol), in 30 mL of THF and 15 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et_2O) to afford **2c** (1.80 g, 5.10 mmol, 88%) as a white solid (mp 64 °C). ¹H NMR (400 MHz, CDCl_3): δ 7.58 (d, $J = 8.9$ Hz, 1H), 7.26 (s,

1H), 6.88 (dd, $J = 8.9, 2.9$ Hz, 1H), 5.44 (s, 1H), 3.90–3.70 (s, 3H). ¹³C NMR (100 MHz, CDCl_3): δ 158.9, 137.2, 128.2, 122.7 (q, $J = 290$ Hz), 117.2 (quint, $J = 3.4$ Hz), 117.0, 110.3, 80.1 (quint, $J = 30.4$ Hz), 55.8. ¹⁹F NMR (376 MHz, CDCl_3): δ -73.7 (s, 6F). IR: $\nu = 3484, 2926, 1601, 1474, 1374, 1219, 1048, 960, 820, 735$ cm^{-1} . HRMS (ESI⁺) calc. for $\text{C}_{10}\text{H}_7\text{BrF}_6\text{NaO}_2$ [$\text{M} + \text{Na}$]⁺ 374.9426; found 374.9444.

2-(2-Bromo-5-nitrophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2d**). Following the general procedure C with **6d** (796.8 mg, 1.81 mmol), in 9 mL of THF and 4.5 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 15% Et_2O) to afford **2d** (500 mg, 1.36 mmol, 75%) as a white solid (mp 67 °C). ¹H NMR (400 MHz, CDCl_3): δ 8.61 (s, 1H), 8.16 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.96 (d, $J = 8.8$ Hz, 1H), 5.00 (s, 1H). ¹³C NMR (100 MHz, CDCl_3): δ 138.3, 128.4, 125.8, 125.4, 120.9, 119.4 (q, $J = 290$ Hz), 80.3. ¹⁹F NMR (376 MHz, CDCl_3): δ -73.5 (s, 6F, F9). IR: $\nu = 3478, 2956, 1580, 1483, 1425, 1364, 1208, 1054, 988, 952, 819$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_9\text{H}_3\text{BrF}_6\text{NO}_3$ [$\text{M} - \text{H}$]⁻ 365.9206; found 365.9200.

2-(2-Bromo-5-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2e**). Following the general procedure C with **6e** (1.47 g, 3.56 mmol), in 18 mL of THF and 9 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et_2O) to afford **2e** (1.12 g, 3.28 mmol, 92%) as an orange liquid. ¹H NMR (400 MHz, CDCl_3): δ 7.68 (dd, $J_{\text{H-H}} = 8.9$ Hz, $J_{\text{H-F}} = 5.6$ Hz, 1H), 7.45 (d, $J_{\text{H-F}} = 8.8$ Hz, 1H), 7.09 (ddd, $J_{\text{H-H}} = 8.9, 3.0$ Hz, $J_{\text{H-F}} = 6.8$ Hz, 1H), 5.30 (s, 1H, OH). ¹³C NMR (100 MHz, CDCl_3): δ 161.5 (d, $J = 250$ Hz), 138.1 (d, $J = 7.8$ Hz), 129.3, 122.7 (q, $J = 290$ Hz), 119.2 (d, $J = 21.9$ Hz), 118.4 (d, $J = 26.8$ Hz), 114.8 (d, $J = 3.6$ Hz), 80.0 (t, $J = 29.4$ Hz). ¹⁹F NMR (376 MHz, CDCl_3): δ -73.7 (s, 6F), -111.5 – -111.7 (m, 1F). IR: $\nu = 3496, 1587, 1476, 953, 848, 753$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_9\text{H}_3\text{BrF}_7\text{O}$ [$\text{M} - \text{H}$]⁻ 338.9261; found 338.9248.

2-(2-Bromo-4-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2f**). Following the general procedure C with **6f** (1.19 g, 2.28 mmol), in 11 mL of THF and 5.5 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et_2O) to afford **2f** (700 mg, 2.05 mmol, 90%) as an orange liquid. ¹H NMR (300 MHz, CDCl_3): δ 7.72 (br s, 1H), 7.47 (dd, $J_{\text{H-H}} = 2.8$ Hz, $J_{\text{H-F}} = 8.0$ Hz, 1H), 7.15 (ddd, $J_{\text{H-H}} = 9.4, 2.8$ Hz, $J_{\text{H-F}} = 7.0$ Hz, 1H), 5.08 (s, 1H). ¹³C NMR (75 MHz, CDCl_3): δ 162.7 (d, $J = 256$ Hz), 132.0, 124.0 (d, $J = 24.6$ Hz), 123.9, 122.8 (q, $J = 287$ Hz), 121.4 (d, $J = 9.3$ Hz), 115.3 (d, $J = 21.0$ Hz), 80.1. ¹⁹F NMR (282 MHz, CDCl_3): δ -73.9 (s, 6F), -108.5 (s). IR: $\nu = 3503, 2359, 1604, 1582, 1496, 1207, 1155, 1105, 1040, 963, 938, 866, 819, 752$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_9\text{H}_3\text{BrF}_7\text{O}$ [$\text{M} - \text{H}$]⁻ 338.9261; found 338.9249.

2-(2-Bromo-4-(trifluoromethyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2g**). Following the general procedure C with **6g** (1.64 g, 3.55 mmol), in 18 mL of THF and 9 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 1% Et_2O) then petroleum ether 10% Et_2O) to afford **2g** (1.25 g, 3.20 mmol, 90%) as an orange liquid. ¹H NMR (400 MHz, CDCl_3): δ 7.99 (d, $J = 0.8$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.70–7.66 (m, 1H), 5.24 (s, 1H, OH). ¹³C NMR (100 MHz, CDCl_3): δ 133.8 (q, $J = 3.9$ Hz), 133.7 (q, $J = 33.8$ Hz), 131.5, 131.2, 124.7, 122.5 (q, $J = 273$ Hz), 122.4 (q, $J = 289$ Hz), 121.2, 80.3 (t, $J = 30.0$ Hz). ¹⁹F NMR (376 MHz, CDCl_3): δ -63.5 (s, 3F), -73.5 (s, 6F). IR: $\nu = 3482, 2930, 1460, 1374, 1219, 1048, 1140, 1089, 1012, 964, 882, 876, 816$ cm^{-1} . HRMS (ESI⁻) calc. for $\text{C}_{10}\text{H}_3\text{BrF}_9\text{O}$ [$\text{M} - \text{H}$]⁻ 388.9229; found 388.9200.

2-(2-Bromo-3-methylphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**2h**). Following the general procedure C with **6h** (1.12 g, 2.93 mmol), in 15 mL of THF and 7.5 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et_2O) to afford **2h** (900 mg, 2.67 mmol, 91%) as a white solid (mp 54 °C). ¹H NMR (400 MHz, CDCl_3): δ 7.57 (d, $J = 8.1$ Hz, 1H), 7.41–7.39 (m, 1H), 7.32 (t, $J = 8.1$ Hz, 1H), 5.82 (s, 1H), 2.50 (s, 3H). ¹³C NMR (100 MHz, CDCl_3): δ 141.4, 133.1, 128.4 (quint, $J = 3.1$ Hz), 127.9, 127.5, 123.4, 122.8 (q, $J = 293$ Hz), 80.9 (quint, $J = 29.9$ Hz), 25.1. ¹⁹F NMR (376 MHz, CDCl_3): δ -73.2 (s, 6F, F9). IR: $\nu = 3482, 2928, 1519, 1472, 1451, 1365, 1255, 1202, 1187, 1141, 1098, 1018, 971, 950,$

819 cm⁻¹. HRMS (ESI⁻) calc. for C₁₀H₆BrF₆O [M - H]⁻ 334.9512; found 334.9503.

2-(1-Bromonaphthalen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol (2i). Following the general procedure C with **6i** (1.91 g, 3.48 mmol), in 21 mL of THF and 10.5 mL of 6 M HCl. The crude product was purified by flash column chromatography (petroleum ether 5% Et₂O) to afford **2i** (1.30 g, 3.48 mmol, 81%) as a white solid (mp 65 °C). ¹H NMR (400 MHz, CDCl₃): δ 8.54–8.49 (m, 1H), 7.92–7.84 (m, 2H), 7.79–7.73 (m, 1H), 7.72–7.62 (m, 2H), 5.94 (s, 1H, OH). ¹³C NMR (100 MHz, CDCl₃): δ 134.7, 133.1, 128.8, 128.7, 128.6, 128.2, 128.0, 126.0, 125.6 (quint, J = 3.3 Hz), 123.0, 122.9 (q, J = 289 Hz), 81.3 (quint, J = 30.4 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -72.8 (s, 6F). IR: ν = 3447, 1206, 1148, 1097, 994, 947, 861, 809, 745 cm⁻¹. HRMS (ESI⁻) calc. for C₁₃H₆BrF₆O [M - H]⁻ 370.9512; found 370.9495.

Procedure D: Preparation of Bis(α,α-bis(trifluoromethyl)arenemethanolato-(2)C², O) Silanes. To a stirred solution of alcohol **2** (1.00 equiv) in diethyl ether (0.3 M) was added NaH (60%) (1.1 equiv) at room temperature. The mixture was stirred for 30 min and cooled to -78 °C. A solution of tBuLi (1.6 M in pentane) (2.20 equiv) was added dropwise and the reaction was warmed to 0 °C. Silicon tetrachloride (0.6 equiv) was added dropwise and the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with H₂O and extracted with Et₂O (30 mL). The ethereal phase was washed with HCl (0.5 M) (3 × 20 mL), H₂O (20 mL), and dried over MgSO₄. The solvent was removed under reduced pressure to give the crude product as an orange oil. The residue was crystallized with hexane to obtain the desired product.

Due to their high reactivity, attempts to characterize spirosilanes **3** by HRMS led to the observation of the corresponding hydroxy or methoxy adducts.

3,3,3',3'-Tetrakis(trifluoromethyl)-1,1'(3H,3'H)-spirobi-[2,1-benzoxasilole] (1). Following the general procedure D with **2a** (1.75 g, 5.42 mmol), NaH (60%, 238.4 mg, 5.96 mmol), tBuLi (1.6 M, 7.45 mL, 11.92 mmol), and SiCl₄ (372.3 μL, 3.25 mmol) in 6.5 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **1** (1.00 g, 1.95 mmol, 72%) as a white solid (mp 132 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 7.98–7.86 (m, 6H, arom.), 7.82–7.79 (m, 2H, arom.). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 142.0, 135.3, 134.2, 132.5, 130.0, 126.0, 124.9 (q, J = 285 Hz), 83.2. ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -76.5 (s, 12F, CF₃). ²⁹Si NMR (119 MHz, CDCl₃): δ 7.5. The spectroscopic data were consistent with those reported in the literature.^{6b}

5,5'-Dimethyl-3,3,3',3'-tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3b). Following the general procedure D with **2b** (1.01 g, 3.01 mmol), NaH (60%, 132.4 mg, 3.31 mmol), tBuLi (1.6 M, 4.14 mL, 6.62 mmol), and SiCl₄ (206.2 μL, 1.80 mmol) in 10 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3b** (0.58 g, 1.07 mmol, 71%) as a white solid (mp 154 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.60 (s, 2H), 7.53 (d, J = 7.5 Hz, 2H), 7.43 (d, J = 7.5 Hz, 2H), 2.51 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 144.3, 142.3, 133.3, 132.7, 126.0 (quint, J = 1.8 Hz), 124.4, 123.8 (q, J = 282 Hz), 82.7 (quint, J = 31.6 Hz), 22.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -75.9 (q, J = 8.9 Hz, 6F), -76.3 (q, J = 8.9 Hz, 6F). ²⁹Si NMR (119 MHz, CDCl₃): δ 7.7. IR: ν = 2928, 1607, 1312, 1281, 1213, 1174, 1106, 1084, 979, 906, 852, 824 cm⁻¹. HRMS (ESI⁻) calc. for C₂₁H₁₅F₁₂O₃Si [M + CH₃O]⁻ 571.0604; found 571.0584.

5,5'-Dimethoxy-3,3,3',3'-tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3c). Following the general procedure D with **2c** (988.6 mg, 2.80 mmol), NaH (60%, 123.2 mg, 3.08 mmol), tBuLi (1.6 M, 3.85 mL, 6.16 mmol), and SiCl₄ (192.5 μL, 1.68 mmol) in 9 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3c** (0.56 g, 0.98 mmol, 70%) as a white solid (mp 112 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, J = 8.2 Hz, 2H), 7.26 (s, 2H), 7.15 (dd, J = 8.2, 2.2 Hz, 2H), 3.91 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 163.8, 144.0, 134.6, 122.2 (q, J = 283 Hz), 118.3, 118.2, 110.8 (quint, J = 1.6 Hz), 82.4 (quint, J = 31.7 Hz), 55.8. ¹⁹F NMR (376 MHz, CDCl₃): δ -75.9 (q, J = 9.0 Hz, 6F), -76.4 (q, J = 9.0 Hz, 6F). ²⁹Si NMR (79 MHz, CDCl₃): δ 7.2. IR: ν = 2947,

1602, 1473, 1281, 1219, 1084, 1032, 980, 852, 744, 708, 689 cm⁻¹. HRMS (ESI⁻) calc. for C₂₁H₁₅F₁₂O₃Si [M + CH₃O]⁻ 603.0503; found 603.0520.

5,5'-Difluoro-3,3,3',3'-tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3e). Following the general procedure D with **2e** (518.4 g, 1.52 mmol), NaH (60%, 66.8 mg, 1.67 mmol), tBuLi (1.6 M, 2.09 mL, 3.34 mmol), and SiCl₄ (104.3 μL, 0.91 mmol) in 5 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3e** (0.28 g, 0.51 mmol, 67%) as a white solid (mp 150 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.66 (dd, J_{H-F} = 5.5 Hz, J_{H-H} = 8.3 Hz, 2H), 7.52 (d, J_{H-F} = 9.0 Hz, 2H), 7.37 (dt, J_{H-F} = 8.3 Hz, J_{H-H} = 8.3, 2.2 Hz, 2H). ¹³C NMR (150 MHz, CDCl₃): δ 166.1 (d, J = 256 Hz), 144.6, 135.6 (d, J = 9.2 Hz), 122.7, 122.4 (q, J = 288 Hz), 119.8 (d, J = 21.6 Hz), 113.5 (d, J = 26.4 Hz), 82.4 (t, J = 30.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -75.9 (q, J = 8.8 Hz, 6F), -76.4 (q, J = 8.8 Hz, 6F), -102.9 – -103.0 (m, 2F). ²⁹Si NMR (119 MHz, CDCl₃/Trifluorotoluene (1/4)): δ -50.1. IR: ν = 1345, 1274, 1215, 1160, 1106, 1080, 999, 978, 913, 871, 832, 743, 707, 672, 641, 614 cm⁻¹. HRMS (ESI⁻) calc. for C₁₉H₉F₁₄O₃Si [M + CH₃O]⁻ 579.0103; found 579.0088.

6,6'-Difluoro-3,3,3',3'-tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3f). Following the general procedure D with **2f** (692.2 mg, 2.03 mmol), NaH (60%, 89.2 mg, 2.23 mmol), tBuLi (1.6 M, 2.79 mL, 4.47 mmol), and SiCl₄ (140 μL, 1.22 mmol) in 6.8 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3f** (0.36 g, 0.66 mmol, 65%) as a white solid (mp 131 °C). ¹H NMR (300 MHz, acetone-*d*₆): δ 7.75 (dd, J_{H-H} = 2.7 Hz, J_{H-F} = 8.7 Hz, 2H), 7.72–7.66 (s, 2H), 7.37–7.29 (td, J_{H-H} = 8.6, 2.7 Hz, J_{H-F} = 8.6 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 164.8 (d, J = 255 Hz), 137.3, 130.0 (d, J = 6.4 Hz), 127.8, 122.0 (q, J = 284 Hz), 121.8 (q, J = 283 Hz), 121.5 (d, J = 23.6 Hz), 119.8 (d, J = 21.2 Hz), 82.6 (t, J = 32.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -76.0 (q, J = 8.8 Hz, 6F), -76.5 (q, J = 8.8 Hz, 6F), -108.2 (s, 2F). ²⁹Si NMR (119 MHz, CDCl₃): δ 4.9. IR: ν = 1581, 1514, 1471, 1273, 1213, 1103, 1068, 970, 928, 836 cm⁻¹. HRMS (ESI⁻) calc. for C₁₉H₉F₁₄O₃Si [M + CH₃O]⁻ 579.0103; found 579.0124.

3,3,3',3',6,6'-Hexakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3g). Following the general procedure D with **2g** (567 mg, 1.45 mmol), NaH (60%, 63.8 mg, 1.595 mmol), tBuLi (1.6 M, 1.99 mL, 3.19 mmol), and SiCl₄ (100 μL, 0.87 mmol) in 4.8 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3g** (0.34 g, 0.53 mmol, 73%) as a white solid (mp 162 °C). ¹H NMR (400 MHz, CDCl₃): δ 8.05–7.97 (m, 4H), 7.90 (s, 2H). ¹³C NMR (150 MHz, CDCl₃): δ 145.3, 134.3 (q, J = 33.0 Hz), 130.7, 130.5, 128.1, 126.4, 123.3 (q, J = 273 Hz), 121.8 (q, J = 288 Hz), 121.5 (q, J = 280 Hz), 82.9. ¹⁹F NMR (376 MHz, CDCl₃): δ -63.1 (s, 6F), -75.6 (q, J = 8.6 Hz, 6F), -76.0 (q, J = 8.6 Hz, 6F). IR: ν = 1331, 1274, 1216, 1199, 1137, 1102, 1086, 1069, 982, 968, 921, 842, 754, 732, 709, 639, 620 cm⁻¹. HRMS (ESI⁻) calc. for C₂₁H₉F₁₈O₃Si [M + CH₃O]⁻ 679.0039; found 679.0015.

7,7'-dimethyl-3,3,3',3'-tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[benzo[*c*][1,2]oxasilole] (3h). Following the general procedure D with **2h** (684.2 mg, 2.03 mmol), NaH (60%, 89.2 mg, 2.23 mmol), tBuLi (1.6 M, 2.79 mL, 4.47 mmol), and SiCl₄ (140 μL, 1.22 mmol) in 6.8 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3h** (0.30 g, 0.55 mmol, 54%) as a white solid (mp 182 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.65–7.58 (m, 4H), 7.45–7.39 (m, 2H), 2.28 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 145.1, 142.0, 133.7, 132.0, 127.2, 122.9, 122.5 (q, J = 285 Hz), 122.0 (q, J = 286 Hz), 82.7, 22.2. ¹⁹F NMR (282 MHz, CDCl₃): δ -75.3 (q, J = 9.0 Hz, 6F), -76.3 (q, J = 9.0 Hz, 6F). ²⁹Si NMR (119 MHz, CDCl₃): δ 8.2. IR: ν = 2927, 1591, 1467, 1308, 1278, 1254, 1210, 1158, 1136, 1110, 1075, 1044, 974, 906, 850 cm⁻¹. HRMS (ESI⁻) calc. for C₂₀H₁₃F₁₂O₃Si [M + HO]⁻ 557.0448; found 557.0436.

3,3,3',3'-Tetrakis(trifluoromethyl)-3H,3'H-1,1'-spirobi[naphtho[1,2-*c*][1,2]oxasilole] (3i). Following the general procedure D with **2i** (307.8 mg, 0.825 mmol), NaH (60%, 36.3 mg, 0.907 mmol), tBuLi (1.6 M, 1.14 mL, 1.82 mmol), and SiCl₄ (56.7 μL, 0.495 mmol) in 2.75 mL of Et₂O. The crude product was purified by crystallization from hexane to afford **3i** (0.20 g, 0.33 mmol, 80%) as a white solid

(mp 196 °C). ¹H NMR (400 MHz, CDCl₃): δ 8.25 (d, *J* = 8.0 Hz, 2H), 8.01 (d, *J* = 8.3 Hz, 2H), 7.93 (d, *J* = 8.0 Hz, 2H), 7.62–7.58 (m, 2H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.43–7.39 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 142.7, 135.0, 134.7, 134.2, 128.8, 128.7, 128.5, 128.2 (d, *J* = 2.5 Hz), 127.7, 122.6 (q, *J* = 284 Hz), 122.1 (q, *J* = 284 Hz), 121.6 (quint, *J* = 1.7 Hz), 83.1 (quint, *J* = 31.5 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -74.7 (q, *J* = 9.2 Hz, 6F), -75.6 (q, *J* = 9.2 Hz, 6F). ²⁹Si NMR (119 MHz, CDCl₃): δ 9.4. IR: *ν* = 2930, 1281, 1204, 1157, 1100, 1040, 976, 744 cm⁻¹. HRMS (ESI⁻) calc. for C₂₇H₁₃F₁₂O₃Si [M + CH₃O]⁻ 643.0604; found 643.0580.

Procedure E-a: Preparation of Sodium bis[α,α-bis(trifluoromethyl)arenemethanolato(2-)-C²,O]fluorosilicate. To a stirred solution of spiro silane 3 (1.00 equiv) in acetone (0.05 M) and 0.1% H₂O was added sodium fluoride (4.00 equiv). The progress of the reaction was monitored by ¹⁹F NMR. The excess of sodium fluoride was filtered off and the filtrate was evaporated under reduced pressure to afford the pure product.

Procedure E-b: Preparation of Tetrabutylammonium bis[α,α-bis(trifluoromethyl)arenemethanolato(2-)-C²,O]fluorosilicate. To a stirred solution of spiro silane 3 (1.00 equiv) in dichloromethane (0.05 M) was added TBAF (1 M in THF, 1.00 equiv). The progress of the reaction was monitored by ¹⁹F NMR. The organic phase was washed with H₂O, dried over MgSO₄, and evaporated under reduced pressure to afford the pure product.

Sodium Bis[α,α-bis(trifluoromethyl)benzenemethanolato(2-)-C²,O]fluoro silicate (7a). Following the general procedure E-a with 3a (307.4 mg, 0.60 mmol), in 12 mL of acetone and 12 μL of water, to afford 7a (0.32 g, 0.58 mmol, 96%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ = 8.23–8.20 (m, 2H, arom.), 7.59–7.55 (m, 2H, arom.), 7.43–7.39 (m, 4H, arom.). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 142.8 (d, *J* = 16.0 Hz), 142.5, 138.1, 129.7, 129.2, 126.8 (q, *J* = 288 Hz), 124.3 (quint, *J* = 2.0 Hz), 81.0 (quint, *J* = 28.6 Hz). ¹⁹F NMR (376 MHz, acetone-*d*₆): -75.7 – -75.8 (m, 6F, CF₃), -75.9 (q, *J* = 9.0 Hz, 6F, CF₃), -132.2 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -73.7 (d, *J* = 23.6 Hz). IR: *ν* = 1446, 1275, 1190, 1142, 1087, 969, 768, 739 cm⁻¹. HRMS (ESI⁻) calc. for C₁₈H₈F₁₃O₂Si [M - Na]⁻ 531.0091; found 531.0090.

Sodium Bis[α,α-bis(trifluoromethyl)-5-methylbenzenemethanolato(2-)-C²,O] fluoro silicate (7b). Following the general procedure E-a with 3b (97.3 mg, 0.18 mmol), in 3.6 mL of acetone and 3.6 μL of water, to afford 7b (0.1 g, 0.17 mmol, 94%) as a white solid (mp >260 °C). ¹H NMR (300 MHz, acetone-*d*₆): δ 8.08 (d, *J* = 7.5 Hz, 2H), 7.36 (s, 2H), 7.18 (d, *J* = 7.5 Hz, 2H), 2.36 (s, 6H). ¹³C NMR (75 MHz, acetone-*d*₆): δ 143.0, 139.7 (d, *J* = 15.9 Hz), 139.3, 138.0, 130.2, 125.4 (q, *J* = 289 Hz), 124.8 (quint, *J* = 1.9 Hz), 81.0 (quint, *J* = 28.7 Hz), 21.6. ¹⁹F NMR (282 MHz, acetone-*d*₆): δ -75.5 (m, 6F), -75.7 (t, *J* = 8.3 Hz, 6F), -132.1 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -77.0 (d, *J* = 226.9 Hz). IR: *ν* = 1701, 1609, 1272, 1207, 1162, 1082, 968, 851, 710, 668 cm⁻¹. HRMS (ESI⁻) calc. for C₂₀H₁₂F₁₃O₂Si [M - Na]⁻ 559.0404; found 559.0398.

Sodium Bis[α,α-bis(trifluoromethyl)-5-methoxybenzenemethanolato(2-)-C²,O] fluoro silicate (7c). Following the general procedure E-a with 3c (38.9 mg, 0.068 mmol), in 1.4 mL of acetone and 1.4 μL of water, to afford 7c (0.04 g, 0.065 mmol, 96%) as a white solid (mp >260 °C). ¹H NMR (300 MHz, acetone-*d*₆): δ 8.09 (d, *J* = 8.2 Hz, 2H), 7.06 (s, 2H), 6.97 (d, *J* = 8.2 Hz, 2H), 3.81 (s, 6H). ¹³C NMR (75 MHz, acetone-*d*₆): δ 161.7, 139.1, 133.8 (d, *J* = 16.3 Hz), 125.3 (q, *J* = 289 Hz), 115.4, 115.2, 109.9 (quint, *J* = 1.6 Hz), 81.0 (quint, *J* = 28.6 Hz), 55.4. ¹⁹F NMR (282 MHz, acetone-*d*₆): δ -75.7 – -75.9 (m, 6F), -75.9 – -76.0 (m, 6F), -132.1 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -77.2 (d, *J* = 225 Hz). IR: *ν* = 2938, 1701, 1599, 1473, 1270, 1213, 1165, 1080, 1032, 968, 851, 709 cm⁻¹. HRMS (ESI⁻) calc. for C₂₀H₁₂F₁₃O₄Si [M - Na]⁻ 591.0303; found 591.0320.

Sodium Bis[α,α-bis(trifluoromethyl)-5-fluorobenzenemethanolato(2-)-C²,O]fluoro silicate (7e). Following the general procedure E-a with 3e (29 mg, 0.053 mmol), in 1 mL of acetone and 1 μL of water, to afford 7e (0.03 g, 0.05 mmol, 94%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 8.18 (dd, *J*_{H-H} = 6.5 Hz, *J*_{H-H} = 8.2 Hz, 2H), 7.22 (d, *J*_{H-F} = 9.8 Hz, 2H), 7.17 (ddd, *J*_{H-H} =

9.3 Hz, *J*_{H-H} = 8.2, 2.3 Hz, 2H). ¹³C NMR (100 MHz, acetone-*d*₆): δ 164.7 (d, *J* = 245 Hz), 144.8 (d, *J* = 7.6 Hz), 139.8 (d, *J* = 8.2 Hz), 138.5, 125.2 (q, *J* = 293 Hz), 125.0 (q, *J* = 288 Hz), 116.6 (d, *J* = 20.3 Hz), 111.1 (d, *J* = 22.9 Hz), 80.5 (t, *J* = 30.9 Hz). ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -76.0 (td, *J* = 9.3, 3.5 Hz, 6F), -76.3 (q, *J* = 9.3 Hz, 6F), -115.0 (td, *J* = 9.5, 6.5 Hz, 2F), -132.1 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -79.3 (d, *J* = 228 Hz). IR: *ν* = 2938, 1375, 1325, 1289, 1167, 1044, 979, 835 cm⁻¹. HRMS (ESI⁻) calc. for C₁₈H₆F₁₅O₂Si [M - Na]⁻ 566.9903; found 566.9890.

Sodium Bis[α,α-bis(trifluoromethyl)-4-fluorobenzenemethanolato(2-)-C²,O]fluoro silicate (7f). Following the general procedure E-a with 3f (28 mg, 0.051 mmol), in 1 mL of acetone and 1 μL of water, to afford 7f (0.03 g, 0.05 mmol, 97%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 7.71 (dd, *J*_{H-H} = 2.7 Hz, *J*_{H-F} = 9.0 Hz, 2H), 7.45–7.40 (m, 2H), 7.00 (td, *J*_{H-H} = 2.7 Hz, *J*_{H-F} = 8.5 Hz, 2H). ¹³C NMR (150 MHz, acetone-*d*₆): δ 164.5 (d, *J* = 246 Hz), 125.7 (d, *J* = 17.6 Hz), 137.9, 126.1, 125.0 (q, *J* = 293 Hz), 123.2 (d, *J* = 19.5 Hz), 117.1 (d, *J* = 23.6 Hz), 80.5 (t, *J* = 28.9 Hz). ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -76.0 – -76.1 (m, 6F), -76.4 (q, *J* = 9.3 Hz, 6F), -116.7 (td, *J* = 8.8, 4.7 Hz, 2F), -132.3 (s, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -80.5 (d, *J* = 230 Hz). IR: *ν* = 2965, 1567, 1510, 1378, 1342, 1258, 1157, 1031, 995, 857, 753 cm⁻¹. HRMS (ESI⁻) calc. for C₁₉H₉F₁₄O₃Si [M - Na + CH₃O]⁻ 579.0103; found 579.0088.

Sodium Bis[α,α-bis(trifluoromethyl)-4-trifluoromethylbenzenemethanolato(2-)-C²,O]fluoro silicate (7g). Following the general procedure E-a with 3g (27.2 mg, 0.042 mmol), in 1 mL of acetone and 1 μL of water, to afford 7g (0.03 g, 0.04 mmol, 95%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 8.54 (s, 2H), 7.80–7.73 (m, 4H). ¹³C NMR (150 MHz, acetone-*d*₆): δ 146.3, 144.1 (q, *J* = 16.8 Hz), 134.6 (q, *J* = 3.9 Hz), 131.4 (q, *J* = 31.2 Hz), 127.1 (q, *J* = 3.9 Hz), 125.8 (q, *J* = 272 Hz), 125.2, 125.1 (dq, *J* = 287, 6.1 Hz), 124.8 (q, *J* = 285 Hz), 80.9 (t, *J* = 29.5 Hz). ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -62.9 (s, 6F), -75.8 – -75.9 (m, 6F), -76.3 (q, *J* = 9.2 Hz, 6F), -132.9 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -79.8 (dt, *J* = 228, 5.4 Hz). IR: *ν* = 1330, 1269, 1216, 1193, 1137, 1087, 1072, 967, 928, 840, 762, 737, 709 cm⁻¹. HRMS (ESI⁻) calc. for C₂₀H₆F₁₉O₂Si [M - Na]⁻ 666.9839; found 666.9826.

Tetrabutylammonium Bis[α,α-bis(trifluoromethyl)-3-methylbenzenemethanolato(2-)-C²,O]fluoro silicate (7h). Following the general procedure E-b with 3h (77.8 mg, 0.144 mmol), in 3 mL of acetone and 3 μL of water, to afford 7h (0.11 g, 0.14 mmol, 97%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 7.24 (d, *J* = 6.6 Hz, 2H), 7.13–7.06 (m, 4H), 3.47–3.41 (m, 8H), 2.56 (s, 6H), 1.88–1.77 (m, 8H), 1.43 (q, *J* = 7.4 Hz, 8H), 0.95 (t, *J* = 7.4 Hz, 12H). ¹³C NMR (100 MHz, acetone-*d*₆): δ 151.7 (d, *J* = 68.5 Hz), 143.2 (d, *J* = 2.4 Hz), 135.5 (d, *J* = 4.3 Hz), 130.5, 126.9, 125.2 (q, *J* = 285 Hz), 124.9 (q, *J* = 285 Hz), 120.8, 79.6, 59.4, 59.3, 24.4, 22.8, 20.4, 20.3, 13.8. ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -75.7 (q, *J* = 8.9 Hz, 6F), -76.2 (q, *J* = 8.8 Hz, 6F), -99.5 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -81.6 (d, *J* = 328 Hz). IR: *ν* = 2967, 2880, 1456, 1381, 1284, 1239, 1211, 1182, 1142, 1113, 1050, 971, 881, 840, 783, 744, 727, 713 cm⁻¹. HRMS (ESI⁻) calc. for C₂₀H₁₂F₁₃O₂Si [M - TBA]⁻ 559.0404; found 559.0398.

Sodium Bis[α,α-bis(trifluoromethyl)naphthalenemethanolato(2-)-C²,O]fluoro silicate (7i). Following the general procedure E-a with 3i (95 mg, 0.155 mmol), in 3.1 mL of acetone and 3.1 μL of water, to afford 7i (0.10 g, 0.15 mmol, 97%) as a white solid (mp >260 °C). ¹H NMR (400 MHz, acetone-*d*₆): δ 8.71–8.65 (m, 2H), 7.89–7.84 (m, 2H), 7.82–7.77 (m, 2H), 7.63–7.57 (m, 2H), 7.49–7.43 (m, 4H). ¹³C NMR (75 MHz, acetone-*d*₆): δ 152.9 (d, *J* = 67.5 Hz), 137.5 (d, *J* = 2.0 Hz), 135.4, 133.1, 132.8 (d, *J* = 4.4 Hz), 128.3, 128.1, 126.3, 125.4, 125.3 (q, *J* = 287 Hz), 124.8 (q, *J* = 285 Hz), 121.8, 80.5 (quint, *J* = 30.4 Hz). ¹⁹F NMR (376 MHz, acetone-*d*₆): δ -75.3 (q, *J* = 9.0 Hz, 6F), -75.9 (q, *J* = 9.0 Hz, 6F), -94.3 (s, 1F, Si-F). ²⁹Si NMR (119 MHz, acetone-*d*₆): δ -80.9 (d, *J* = 322.6 Hz). IR: *ν* = 1698, 1623, 1508, 1281, 1189, 1129, 1041, 972, 815, 751, 679, 644 cm⁻¹. HRMS (ESI⁻) calc. for C₂₆H₁₂F₁₃O₂Si [M - Na]⁻ 631.0404; found 631.0424.

■ ASSOCIATED CONTENT

■ Supporting Information

NMR spectra and X-ray diffraction data (CIF file). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: jean-philippe.goddard@uha.fr.

*E-mail: louis.fensterbank@upmc.fr.

Present Address

Jean-Philippe Goddard, Laboratoire de Chimie Organique et Bioorganique EA 4566, Université de Haute-Alsace, Ecole Nationale Supérieure de Chimie de Mulhouse, 3 rue Alfred Werner, F-68093 Mulhouse Cedex, France.

Author Contributions

The experiments were performed by HL, GS, VC, JPG, and CC. LEZ and LK participated to the design of experiments. Crystal structure determinations were determined by LMC. The manuscript was written by JPG and LF. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

LF thanks the Institut Universitaire de France. HL thanks the DGA for a PhD grant. GS thanks the ANR (grant BLAN0309, Radicaux Verts) for postdoctoral fellowship. VC thanks the ANR (NHGX ANR-11-BS07-008) for a postdoctoral fellowship. This work was also supported (postdoctoral grant for CC) by the LabEx MiChem part of French state funds managed by the ANR within the Investissements d'Avenir programme under reference ANR-11-IDEX-0004-02. E. Joubert (DGA) and L. Sinault (DGA) are acknowledged for helpful discussions. Technical assistance was generously offered through FR 2769. Special thanks to Geoffrey Gontard (IPCM) for a crystal structure determination, Omar Khaled (IPCM) for the HRMS spectra and Dr. Sara Kyne (IPCM) for proofreading the article.

■ REFERENCES

- (1) (a) Rundle, R. E. *J. Am. Chem. Soc.* **1947**, *69*, 1327. (b) Pimentel, G. *J. Chem. Phys.* **1951**, *19*, 446.
- (2) (a) Musher, J. I. *Angew. Chem., Int. Ed.* **1969**, *8*, 54. (b) Reed, A.; Schleyer, E.; von, P.; Am, R. *J. Chem. Soc.* **1990**, *112*, 1434. (c) Kutzelnigg, W. *Angew. Chem., Int. Ed.* **1984**, *23*, 272. (d) Martin, J. C. *Science* **1983**, *221*, 509. For reviews, see (e) Akiba, K. *Chemistry of Hypervalent Compounds*; Wiley-VCH, 1999. (f) Weinhold, F.; Landis, C. *Valency and Bonding*; Cambridge University Press: Cambridge, UK, 2005; Chapter 3. (g) Martin, J. C. *Chem. Eng. News* **1984**, *62* (4), 70. (h) Gillespie, R. J.; Robinson, E. A. *Inorg. Chem.* **1995**, *34*, 978.
- (3) Gay-Lussac, J. L.; Thenard, L. J. *Mémoires de Physique et de Chimie de la Société d'Arcueil* **1809**, *2*, 317.
- (4) Conley, B. D.; Yearwood, B. C.; Parkin, S.; Atwood, D. A. *J. Fluor. Chem.* **2002**, *115*, 155 and references cited herein..
- (5) (a) Chuit, C.; Corriu, R. J. P.; Reye, C.; Young, J. C. *Chem. Rev.* **1993**, *93*, 1371. (b) Benaglia, M.; Guizzetti, S.; Pignataro, L. *Coord. Chem. Rev.* **2008**, *252*, 492. (c) Dilman, A. D.; Ioffe, S. L. *Chem. Rev.* **2003**, *103*, 733. (d) Rendler, S.; Oestreich, M. *Synthesis* **2005**, *11*, 1727. (e) Holmes, R. R. *Chem. Rev.* **1996**, *96*, 927.
- (6) (a) Perozzi, E. F.; Martin, J. C. *J. Am. Chem. Soc.* **1979**, *101*, 1591. (b) Perozzi, E. F.; Michalak, R. S.; Figuly, G. D.; Stevenson, W. H.; Dess, D.; Ross, M. R.; Martin, J. C. *J. Org. Chem.* **1981**, *46*, 1049.
- (7) (a) Stevenson, W. H., III; Wilson, S.; Martin, J. C.; Farnham, W. B. *J. Am. Chem. Soc.* **1985**, *107*, 6340. For comparable stabilization by

- geometrical effect, see: (b) Myers, A. G.; Kephart, S. E.; Chen, H. J. *Am. Chem. Soc.* **1992**, *114*, 7922. (c) Denmark, S. E.; Griedel, B. D.; Coe, D. M. *J. Org. Chem.* **1993**, *58*, 988. (d) Matsumoto, K.; Oshima, K.; Utimoto, K. *J. Org. Chem.* **1994**, *59*, 7152. (e) Kinnaird, J. W. A.; Ng, P. Y.; Kubota, K.; Wang, X.; Leighton, J. L. *J. Am. Chem. Soc.* **2002**, *124*, 7920. For one example of hexavalent compound see: (f) Farnham, W. B.; Whitney, J. F. *J. Am. Chem. Soc.* **1984**, *106*, 3992.
- (8) Murakami, M.; Ikai, S.; Yano, T. *Polym. Bull.* **1997**, *39*, 573.
 - (9) Chopra, S. K.; Martin, J. C. *J. Am. Chem. Soc.* **1990**, *112*, 5342.
 - (10) (a) Kano, N.; Miyake, H.; Sasaki, K.; Kawashima, T.; Mizorogi, N.; Nagase, S. *Nat. Chem.* **2010**, *2*, 112. (b) See also: Kira, M.; Sato, K.; Kabuto, C.; Sakurai, H. *J. Am. Chem. Soc.* **1989**, *111*, 3747.
 - (11) Zins, E.-L.; Krim, L.; Lenormand, H.; Goddard, J.-P.; Fensterbank, L. *J. Phys. Chem. A* **2013**, *117*, 3296.
 - (12) Lenormand, H.; Goddard, J.-P.; Fensterbank, L. *Org. Lett.* **2013**, *15*, 748.
 - (13) Barbarich, T. J.; Nolan, B. G.; Tsujioka, S.; Miller, S. M.; Anderson, O. P.; Strauss, S. H. *J. Fluorine Chem.* **2001**, *112*, 335.
 - (14) (a) Farah, B. S.; Gilbert, E. E.; Sibilia, J. P. *J. Org. Chem.* **1965**, *30*, 998. (b) Sepio, J.; Soulen, R. L. *J. Fluorine Chem.* **1984**, *24*, 61.
 - (15) Babadzhanova, L. A.; Kirij, N. V.; Yagupolskii, Y. L.; Tyrrab, W.; Naumann, D. *Tetrahedron* **2005**, *61*, 1813.
 - (16) Prakash, G. K. S.; Yudin, A. K. *Chem. Rev.* **1997**, *97*, 757.
 - (17) For a related preparation of benzoboroxoles, see: (a) Zhdankin, V. V.; Persichini, P. J., III; Zhang, L.; Fix, S.; Kiprof, P. *Tetrahedron Lett.* **1999**, *40*, 6705. For a Grignard approach in phosphorus series, see: (b) Granoth, I.; Martin, J. C. *J. Am. Chem. Soc.* **1979**, *101*, 4618.
 - (18) Beak, P.; Musick, T. J.; Chen, C.-w. *J. Am. Chem. Soc.* **1988**, *110*, 3538.
 - (19) Si-F is a highly energetic bond: 135 kcal/mol. See also: Benson, S. W. *J. Chem. Educ.* **1965**, *42*, 502–518.
 - (20) Farnham, W. B.; Harlow, R. L. *J. Am. Chem. Soc.* **1981**, *103*, 4608.